Lamisil Huidschimmelcrème (Terbinafine Hydrochloride)

Terbinafine inhibits the fungal enzyme squalene epoxidase, which is essential for ergosterol synthesis in the fungal cell membrane. By blocking this pathway, the drug causes toxic squalene buildup and loss of membrane integrity, leading to fungal cell death at the site of application.

The dosing regimen for Lamisil Huidschimmelcrème is determined by the prescribing healthcare professional based on the infection type, severity, patient age, and other clinical factors. Patients should follow the prescriber’s instructions and apply the cream as directed.

Safety data for topical terbinafine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Terbinafine belongs to the allylamine class, which differs from azole antifungals that target lanosterol 14α‑demethylase. Allylamines like terbinafine often achieve rapid fungicidal activity and are effective against many dermatophytes, making them a preferred option for common skin fungal infections.

Store Lamisil Huidschimmelcrème at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct heat, and ensure the cap is tightly closed to maintain stability.

The cream should be applied to clean, dry skin in a thin layer over the affected area, usually twice daily or as directed by a healthcare professional. Hands should be washed before and after application, and the treated skin should be covered only if advised.

Although rare, serious adverse reactions can include allergic contact dermatitis, severe skin reactions such as urticaria, angioedema, or Stevens‑Johnson syndrome. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, swelling, or difficulty breathing.

Individuals with a known hypersensitivity to terbinafine, any component of the cream, or other allylamine antifungals should avoid using the product. Additionally, patients should consult a healthcare provider before use if they are pregnant, breastfeeding, or taking systemic antifungal medications.